There is growing concern that the Fistula First Initiative, KDOQI guidelines, and subsequent pressure from the Centers for Medicare and Medicaid Services lack reasonableness regarding likely success for fistula maturation in a heterogeneous, new-onset dialysis population. Here the various positions are examined from multiple perspectives.

The prevalence of diabetic nephropathy (DN) among diabetic patients seems to be overestimated. Recent studies with renal biopsies show that the incidence of non-diabetic nephropathy (NDN) among diabetic patients is higher than expected. Renal impairment of diabetic patients is frequently attributed to DN without meeting the KDOQI criteria or performing renal biopsy to exclude NDN. In this edito...

the prevalence of chronic kidney disease (ckd), as defined by the nfk-kdoqi (the national kidney foundation kidney disease outcomes quality initiative) guidelines, is a glomerular filtration rate less than 60 ml/min/1.73 m2 or the presence of microalbuminuria. ckd is increasing worldwide, leading to an increased risk of cardiovascular disease. there is general agreement on the importance of an ...

BACKGROUND In many countries, nephrologists follow clinical practice guidelines for mineral bone disorders to control secondary hyperparathyroidism (SHPT) associated with abnormal serum calcium (Ca) and phosphorus (P) levels in patients undergoing maintenance hemodialysis (MHD). The Kidney Disease Outcomes Quality Initiative (KDOQI) Guidelines have long been used in Korea, and this study was un...

Paricalcitol is approved for prevention and therapy of secondary hyperparathyroidism (sHPT) in patients with chronic kidney disease (CKD), with only short-term data in clinical routine settings. A 12-month observational study was conducted in Germany and Austria (90 centers, 761 patients) from 2008 to 2013. Laboratory values, demographical, and clinical data were documented in 629 dialysis pati...

2.1.3: The cause of AKI should be determined whenever possible. (Not Graded) 2.2.1: We recommend that patients be stratified for risk of AKI according to their susceptibilities and exposures. (1B) 2.2.2: Manage patients according to their susceptibilities and exposures to reduce the risk of AKI (see relevant guideline sections). (Not Graded) 2.2.3: Test patients at increased risk for AKI with m...

bisphosphonates. For this reason knowledge of the pharmacokinetics of the various bisphosphonates is a mandatory precondition for their use in severe renal impairment or dialysis dependence. Bone disease is a frequent finding in severe renal impairment (Kidney Disease: Improving Global Outcomes [KDIGO] stages IV & V). Most forms are subsumed under the terms renal osteopathy or renal osteodystro...